Glucuronidation
Glucuronidation is often involved in drug metabolism of substances such as drugs, pollutants, bilirubin, androgens, estrogens, mineralocorticoids, glucocorticoids, fatty acid derivatives, retinoids, and bile acids. These linkages involve glycosidic bonds.[1]
Mechanism
[edit]Glucuronidation consists of transfer of the glucuronic acid component of uridine diphosphate glucuronic acid to a substrate by any of several types of UDP-glucuronosyltransferase. UDP-glucuronic acid (glucuronic acid linked via a glycosidic bond to uridine diphosphate) is an intermediate in the process and is formed in the liver. One example is the N-glucuronidation of an aromatic amine, 4-aminobiphenyl, by UGT1A4 or UGT1A9 from human, rat, or mouse liver.[2]
The substances resulting from glucuronidation are known as glucuronides (or glucuronosides) and are typically much more water-soluble than the non-glucuronic acid-containing substances from which they were originally synthesised. The human body uses glucuronidation to make a large variety of substances more water-soluble, and, in this way, allow for their subsequent elimination from the body through urine or feces (via bile from the liver). Hormones are glucuronidated to allow for easier transport around the body. Pharmacologists have linked drugs to glucuronic acid to allow for more effective delivery of a broad range of potential therapeutics. Sometimes toxic substances are also less toxic after glucuronidation.
The conjugation of xenobiotic molecules with hydrophilic molecular species such as glucuronic acid is known as phase II metabolism.
Sites
[edit]Glucuronidation occurs mainly in the liver, although the enzyme responsible for its catalysis, UDP-glucuronyltransferase, has been found in all major body organs (e.g., intestine, kidneys, brain, adrenal gland, spleen, and thymus).[3][4]
General influencing factors
[edit]Various factors affect the rate of glucuronidation, which in turn will affect these molecules' clearance from the body. Generally, an increased rate of glucuronidation results in a loss of potency for the target drugs or compounds.
| Factor | Effect on glucuronidation[5] | Main drugs or compounds affected[5] | |
|---|---|---|---|
| Age | Infant | ↑ | Chloramphenicol, morphine, paracetamol, bilirubin, steroids |
| Elderly | ↑ or unchanged | No change found for paracetamol, oxazepam, temazepam, or propranolol. Decreased clearance found for codeine-6-glucuronide, and decreased unbound clearance for oxazepam in the very elderly. | |
| Sex | Females | ↓ | Clearance higher in males for paracetamol, oxazepam, temazepam, and propranolol. Possible additive role with CYP1A2 resulting in higher clozapine and olanzapine concentrations in females |
| Males | ↑ | ||
| Body habitus | Overweight | ↑ | Clearance of lorazepam, oxazepam, temazepam, and paracetamol likely the result of an increase in liver size and quantity of enzyme |
| Underweight/malnourished | ↓ | Chloramphenicol, paracetamol | |
| Disease states | Fulminant hepatitis, cirrhosis | ↓ | Zidovudine, oxazepam, lamotrigine |
| Hypothyroidism | ↓ | Oxazepam, paracetamol | |
| HIV | ↓ | Paracetamol | |
| Tobacco smoking | ↑ | Propranolol, oxazepam, lorazepam, paracetamol. Possible additive role with CYP1A2 induction causing decreased clozapine and olanzapine concentration. | |
Affected drugs
[edit]Many drugs which are substrates for glucuronidation as part of their metabolism are significantly affected by inhibitors or inducers of their specific glucuronisyltransferase types:
| Substrate | Inhibitors of glucuronidation[5] | Inducers of glucuronidation[5][6] |
|---|---|---|
| Morphine |
|
|
| Oxazepam |
|
|
| Bilirubin |
| |
| Paracetamol |
|
|
| Androsterone |
|
|
| Carbamazepine- 10,11-transdiol |
|
|
| Codeine |
|
|
| Lamotrigine |
| |
| Lorazepam |
|
|
| Temazepam |
|
|
| Testosterone |
| |
| Zidovudine |
|
References
[edit]- ^ King C, Rios G, Green M, Tephly T (2000). "UDP-glucuronosyltransferases". Curr. Drug Metab. 1 (2): 143–61. doi:10.2174/1389200003339171. PMID 11465080.
- ^ Al-Zoughool M., Talaska, G. (2006). "4-Aminobiphenyl N-glucuronidation by liver microsomes: optimization of the reaction conditions and characterization of the UDP-glucoronosyltransferase isoforms". J. Appl. Toxicol. 26 (6): 524–532. doi:10.1002/jat.1172. PMID 17080401. S2CID 19782863.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Ohno S, Nakajin, Shizuo (2008-10-06). "Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction". Drug Metabolism and Disposition. 37 (1). American Society for Pharmacology and Experimental Therapeutics: 32–40. doi:10.1124/dmd.108.023598. PMID 18838504. S2CID 5150289. Retrieved 2010-11-07.
- ^ Bock K, Köhle C (2005). "UDP-Glucuronosyltransferase 1A6: Structural, Functional, and Regulatory Aspects". Phase II Conjugation Enzymes and Transport Systems. Methods in Enzymology. Vol. 400. pp. 57–75. doi:10.1016/S0076-6879(05)00004-2. ISBN 978-0-12-182805-9. PMID 16399343.
- ^ a b c d Unless else specified in boxes, then reference is: Liston H, Markowitz J, Devane C (2001). "Drug glucuronidation in clinical psychopharmacology". Journal of Clinical Psychopharmacology. 21 (5): 500–515. doi:10.1097/00004714-200110000-00008. PMID 11593076. S2CID 6068811.
- ^ Neil B. Sandson, Drug-Drug Interaction Primer